A detailed history of Marshall Wace, LLP transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 69,042 shares of STTK stock, worth $84,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,042
Previous 77,495 10.91%
Holding current value
$84,231
Previous $692,000 61.56%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.56 - $11.18 $30,092 - $94,504
-8,453 Reduced 10.91%
69,042 $266,000
Q1 2024

May 15, 2024

BUY
$7.37 - $10.09 $571,138 - $781,924
77,495 New
77,495 $692,000
Q1 2022

May 16, 2022

SELL
$4.22 - $8.89 $1.08 Million - $2.27 Million
-255,003 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$8.36 - $21.08 $2.13 Million - $5.38 Million
255,003 New
255,003 $2.17 Million

Others Institutions Holding STTK

About Shattuck Labs, Inc.


  • Ticker STTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,382,000
  • Market Cap $51.7M
  • Description
  • Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...
More about STTK
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.